Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease

Neurobiol Aging. 2006 Sep;27(9):1216-23. doi: 10.1016/j.neurobiolaging.2005.07.010. Epub 2005 Aug 29.

Abstract

Impaired transmission of acetylcholine-mediated signaling by postsynaptic muscarinic M1 receptors has been postulated to underlie the limited efficacy of cholinergic replacement therapies in Alzheimer's disease (AD). However, a clear relationship between the functionality of M1 receptors and dementia severity has not been demonstrated. The present study aims to measure M1 coupling to its nucleotide binding (G-) protein in the AD neocortex, and to correlate neurochemical findings with clinical features. A cohort of dementia patients was longitudinally assessed for cognitive decline, with postmortem neuropathological confirmation of AD diagnosis. Measures of M1 receptor density, M1/G-protein coupling and choline acetyltransferase (ChAT) activities were performed in the frontal and temporal cortex of 24 AD patients as well as in 12 age-matched controls. We found that M1 receptor densities were unchanged in AD, which contrasted with significantly reduced M1 coupling to G-proteins in severely demented AD patients. Loss of M1/G-protein coupling in the frontal cortex, but not the temporal cortex, also correlated with the rate of cognitive decline. Additionally, correlations between M1/G-protein coupling and ChAT activities were demonstrated in both regions. These results suggest that defective coupling of neocortical M1 receptors to G-proteins is a neurochemical substrate of cognitive decline in AD. Based on its associations with ChAT deficits and dementia severity, we propose that M1/G-protein uncoupling may have a significant role in the disease mechanism of AD and thus may be considered to be a potential therapeutic target.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / pathology*
  • Alzheimer Disease / physiopathology*
  • Analysis of Variance
  • Brain Chemistry / drug effects
  • Brain Chemistry / physiology
  • Choline O-Acetyltransferase / metabolism
  • Cognition Disorders / etiology
  • Cognition Disorders / metabolism
  • Dementia / pathology*
  • Dose-Response Relationship, Drug
  • Female
  • GTP-Binding Proteins / physiology*
  • Humans
  • Male
  • Muscarinic Antagonists / pharmacokinetics
  • Neocortex / drug effects
  • Neocortex / pathology
  • Neocortex / physiopathology*
  • Pirenzepine / pharmacokinetics
  • Postmortem Changes
  • Protein Binding / drug effects
  • Psychiatric Status Rating Scales
  • Receptor, Muscarinic M1 / physiology*
  • Tritium / pharmacokinetics

Substances

  • Muscarinic Antagonists
  • Receptor, Muscarinic M1
  • Tritium
  • Pirenzepine
  • Choline O-Acetyltransferase
  • GTP-Binding Proteins